跳轉至內容
Merck

W2020

WR-1065

≥98% (HPLC), reactive oxygen species scavenger, powder

同義詞:

2-[(3-Aminopropyl)amino]ethanethiol dihydrochloride, WR-1065 dihydrochloride

登入 檢視組織與合約價格。

選擇尺寸

變更視圖

關於此項目

經驗公式(希爾表示法):
C5H14N2S · 2HCl
CAS 編號:
分子量::
207.16
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
desiccated
技術服務
需要援助?我們經驗豐富的科學家團隊隨時樂意為您提供支援。
讓我們為您提供幫助


產品名稱

WR-1065, ≥98% (HPLC)

Quality Level

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to off-white

solubility

H2O: ≥20 mg/mL

storage temp.

−20°C

SMILES string

Cl.Cl.NCCCNCCS

InChI

1S/C5H14N2S.2ClH/c6-2-1-3-7-4-5-8;;/h7-8H,1-6H2;2*1H

InChI key

XDRLRDHLCIFZIW-UHFFFAOYSA-N

Biochem/physiol Actions

WR-1065 is a cytoprotective cell-permeable ROS scavenge and an active metabolite of Amifostine.
WR-1065 is cytoprotective cell-permeable reactive oxygen species scavenger and p53 activator and re-activator. Recently shown to have antiretroviral activity and an active metabolite of Amifostine which selectively protects normal tissues from the damaging effects of anti-neoplastic radiation therapy.
WR-1065 is the active metabolite of the prodrug amifostine, generated by alkaline phosphatase. It is found to accumulate in many epithelial tissues. WR-1065 protects cellular membranes and DNA from free radical induced damage.


pictograms

CorrosionExclamation mark

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1

存儲類別/等級

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫



Trevor McKibbin et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 16(3), 1049-1057 (2010-01-28)
We evaluated the pharmacokinetics of amifostine and WR1065 in pediatric patients with newly diagnosed medulloblastoma to assess the influence of patient covariates, including demographics, clinical characteristics, and genetic polymorphisms, on amifostine and WR1065 pharmacokinetic parameters. We assessed the pharmacokinetics of
Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer
Jellema AP, et al.
Cancer, 107(3), 544-553 (2006)
Caroline Prouillac et al.
Free radical biology & medicine, 46(8), 1139-1148 (2009-05-15)
Thiol and aminothiol compounds are among the most efficient chemical radioprotectors. To increase their efficiency, we synthesized two new classes of thiol and aminothiol compounds derived from benzothiazole (T1, T2, AM1, AM2) and thiadiazole (T3, T4, AM3) structures. We examined